Why 10x Genomics Stock Was Sliding This Week

Group 1 - 10x Genomics has faced a decline in stock price, down over 9% week to date due to bearish analyst sentiment [1] - Morgan Stanley analyst Tejas Savant reduced the price target for 10x Genomics from $26 to $18 while maintaining an overweight recommendation [2] - Other analysts, including Canaccord Genuity's Kyle Mikson, have also lowered their price targets, with Mikson adjusting his from $18 to $15 due to macroeconomic uncertainty [4][5] Group 2 - The adjustments in price targets occurred around the time of a legal settlement between 10x Genomics and Bruker, resolving a patent infringement dispute [6] - The settlement is viewed positively, and the company operates in an innovative field, suggesting bullish prospects despite the speculative nature of the investment [7]